Price$4.77-0.22 (-4.41%)
01:30 PM07:45 PM
News · 26 weeks38-75%
2025-12-072026-05-31
Mix1490d
- Other6(43%)
- SEC Filings5(36%)
- Earnings2(14%)
- Insider1(7%)
Latest news
25 items- SECSEC Form SD filed by RxSight Inc.SD - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology ForumALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LA
- SECSEC Form 10-Q filed by RxSight Inc.10-Q - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 unitsRobust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustabilityRecent regulatory approval in New Zealand furthering the company's international footprint and global market opportunity2026 sales and gross margin guidance u
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Present at the Bank of America Healthcare ConferenceALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, col
- SECSEC Form DEFA14A filed by RxSight Inc.DEFA14A - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form DEF 14A filed by RxSight Inc.DEF 14A - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s
- INSIDERSEC Form 4 filed by Goldshleger Ilya4 - RxSight, Inc. (0001111485) (Issuer)
- PRRxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company's pursuit to make customized vision correction widely available to patients. The RxSight® Light Adjustable Lens system is the first and only intraocular lens (IOL) technology that enables doctors to optimize a patient's vision after cataract surgery based on real-world visual feedback. "The 300,000 milestone is a testament to the skill and dedication of the doctors
- PRRxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare ConferenceALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjust
- SECAmendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.SCHEDULE 13G/A - RxSight, Inc. (0001111485) (Subject)
- SECAmendment: SEC Form 8-K/A filed by RxSight Inc.8-K/A - RxSight, Inc. (0001111485) (Filer)
- INSIDERChief Financial Officer Wilterding Mark converted options into 20,441 shares and covered exercise/tax liability with 8,068 shares (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERChief Customer Officer Gaines Scott converted options into 6,261 shares and covered exercise/tax liability with 2,580 shares, increasing direct ownership by 33% to 14,848 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Goldshleger Ilya4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by Officer Weinberg Eric4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Kurtz Ronald M Md4 - RxSight, Inc. (0001111485) (Issuer)
- SECSEC Form EFFECT filed by RxSight Inc.EFFECT - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form POS AM filed by RxSight Inc.POS AM - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form S-8 filed by RxSight Inc.S-8 - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form 10-K filed by RxSight Inc.10-K - RxSight, Inc. (0001111485) (Filer)
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 GuidanceALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growthRxSight's FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from conte
RXST FAQ
7 questionsWhat does RxSight Inc. do?
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based...Where does RXST stock trade?
RxSight Inc. (RXST) is listed on NASDAQ.What sector and industry is RXST in?
RxSight Inc. operates in the Health Care sector, Ophthalmic Goods industry.When did RxSight Inc. go public?
RxSight Inc. (RXST) completed its IPO in 2021.What are analysts saying about RXST?
RxSight Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2026-01-30. Recent price targets range from $900.00 to $2500.00.What companies are similar to RXST?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), BLCO (Bausch + Lomb Corporation), WRBY (Warby Parker Inc.), STAA (STAAR Surgical Company). Compare RXST side-by-side with any of them on Quantisnow.How can I track RXST on Quantisnow?
Quantisnow aggregates RxSight Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXST to receive live email and push alerts on every new disclosure.